In recent years, bezafibrate, a PPARα agonist, elafibranor, a PPARα/δ agonist, seladelpar, a PPARδ agonist, and saroglitazar, a PPARα/γ agonist, have been investigated for the treatment of CLD. Here, PPARA is linked to congenital secretory chloride diarrhea 1.